• Antibodies for Bioanalysis and Drug Monitoring of Daratumumab

Laboratory Products

Antibodies for Bioanalysis and Drug Monitoring of Daratumumab

Feb 21 2022

A range of anti-daratumumab antibodies from Bio-Rad Laboratories, Inc are specific for daratumumab (Darzalex) and inhibit the binding of the drug to its target, CD38. These highly specific and high-affinity recombinant antibodies are suitable for bioanalysis and drug monitoring of daratumumab and its biosimilars. 

Daratumumab is an anticancer drug that binds to the CD38 protein overexpressed in multiple myeloma cells, leading to immune-mediated apoptosis of the tumor cell. The new range of anti-daratumumab antibodies comprises three fully human IgG1 inhibitory antibodies with varying levels of affinity. The antibodies are ideal for use as surrogate positive controls in anti-drug antibody assays, and for the development of pharmacokinetic bridging ELISAs to measure free drug. 

Bio-Rad offers a portfolio of recombinant, monoclonal, nonanimal-derived anti-idiotypic antibodies and drug–target complex binders for the development of highly selective and sensitive assays. These critical reagents enable researchers to develop robust methods in a short timescale and produce translatable and reproducible results. The antibodies are generated using the Human Combinatorial Antibody Libraries (HuCAL®) and CysDisplay®, a proprietary method of phage display, along with guided selection methods to obtain highly targeted reagents. 

“We are pleased to continue the expansion of our range of anti-idiotypic antibodies to support researchers developing novel treatments,” said Amanda Turner, Bio-Rad Product Manager, Life Science Group. “Our recombinant production methods result in batch-to-batch consistency, so researchers can rely on our antibodies to deliver reproducible results over the lifecycle of their bioanalytical assays,” she said. 

The anti-daratumumab antibodies are approved for in vitro research purposes and for commercial applications providing in vitro testing services to support preclinical and clinical drug development.

More information online


Digital Edition

Lab Asia 31.1 - February 2024

February 2024

In This Edition Chromatography Articles - Comparing techniques for flow rate measurement in Liquid Chromatography Mass Spectrometry & Spectroscopy Articles - APGC: A Better Future with...

View all digital editions

Events

IFPAC 2024

Mar 03 2024 Bethesda, MA, USA

SIAF Guangzhou

Mar 04 2024 Guanghzou, China

China Lab 2024

Mar 05 2024 Guangzhou, China

Laborama 2024

Mar 14 2024 Brussels, Belgium

MSACL 2024

Mar 17 2024 Monterey, CA, USA

View all events